Extemporaneous Compounding: Cautions, Controversies and Convenience by Mohiuddin, AK
International Journal of Health and Clinical Research, 2019;2(1):1-16 e-ISSN: 2590-3241, p-ISSN: 2590-325X 
Mohiuddin 
www.ijhcr.com 
International Journal of Health and Clinical Research, 2019; 2(1):1-16 
1 
 
 
 
 
Document heading: Review Article 
Extemporaneous Compounding: Cautions, Controversies and Convenience 
 
AK Mohiuddin* 
Assistant Professor 
Department of Pharmacy, World University of Bangladesh, Bangladesh 
Received: 18-10-2018 / Revised: 28-11-2018 / Accepted: 10-01-2019 
Abstract 
 
The article aims to physico-chemical and economic considerations before compounding; factors and quality control 
issues; compounding support, training, chemical supplies, types of compounding (specially in hospital and 
ambulatory care compounding). It should aid to practice the extemporaneous preparation of basic and advanced 
formulations including pharmacopoeial and non-pharmacopoeial formulations encountered in pharmacy practice, 
together with requisite documentation, labeling, packaging and counseling requirements. Along with this, they have 
to study the analysis of formulations and their components and relate these to the clinical performance of medicines. 
This will help them to investigate, evaluate and report the physical characteristics of formulations including release 
kinetics and relate these to quality control and preformulation requirements; relate the application of quality control, 
quality assurance and the principles of good manufacturing practice to regulation of medicine production in home 
and abroad. 
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Introduction 
 
The FDA defines traditional  pharmacy compounding 
as the combining, mixing, or altering of ingredients to 
create a customized medication for an individual 
patient in response to a licensed practitioner‘s 
prescription. The NABP  further describes 
compounding as the result of a practitioner‘s 
prescription drug order based on the 
practitioner/patient/pharmacist relationship in the 
course of professional practice. 
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Traditional pharmacy compounding plays a valuable 
role in providing access to medications for individuals 
with unique medical needs, which cannot be met with a 
commercially available product. For instance, a 
prescriber may request that a pharmacist compound a 
suspension for a pediatric or geriatric patient unable to 
swallow a medication in its commercially available 
form. In traditional pharmacy compounding, an 
individualized medicine is prepared at the request of a 
prescriber on a small scale.It is obvious that large scale 
manufacturers have very limited opportunity to 
customize dosage strength and dosage forms for a 
customer segment that is not substantially big enough 
due to economies of scale concept of business. Another 
major difference is that compounding pharmacies are 
not required to report adverse events to the FDA, 
whereas adverse event reporting is mandatory for 
manufacturers of FDA-regulated medications. Thus, 
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adverse events associated with compounded drugs may 
be difficult to detect, particularly if the affected  
patients are widely scattered in different geographic 
areas.Registered and skilled pharmacists in practicing 
their art of compounding fills in this gap to meet 
individualized needs. Compounding has always been a 
basic part of pharmacy practice; the drugs, dosage 
forms, and equipment or techniques used are the 
variables. Pharmacists have unique knowledge and 
skills and are not duplicated by any other profession. 
Pharmacy activities to individualize patient therapy 
include compounding and clinical functions. Either 
function in the absence of the other results in placing 
pharmacy in a vulnerable position. It is important to 
entrust a pharmacist‘s expertise to adjust dosage 
quantities, frequencies, and even dosage forms to 
enhance compliance. Pharmacy is a complex mixture 
of different practices and practice sites. No longer is 
pharmacy simply community pharmacy or hospital 
pharmacy. Pharmacy is diverse and offers many 
opportunities for those willing to look around,  find 
their niche and practice pharmacy to meet the needs of 
their own community of patients. Most compounding 
pharmacists appear to be interested and excited about 
their practices. In fact, many pharmacists intimately 
involved in pharmaceutical care have now realized the 
importance of providing individualized patient care 
through the preparation of patient-specific products. 
Compounding pharmacy is not for everyone, but as it 
grows, it will provide an increasingly significant 
number of pharmacists the excitement and fulfillment 
of using their innovative and creative skills to solve 
patient problems. 
 
 
 
 
 
 
Figure 1: Rationale of Extemporaneous compounding (Source: Velpandian T., Das U.S. (2016) 
Extemporaneously Used Drug Formulations for Ocular Emergencies. In: Velpandian T. (eds) Pharmacology of 
Ocular Therapeutics. Adis, Cham 
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Rationale of Extemporaneous Compounding 
An estimate by FDA that 1-10% of all prescriptions 
require compounding was not supported by evidence 
data. EP strategies in clinical studies requires 'fit-for- 
purpose' formulation design and preparation processes, 
as well as administration procedures that are safe, 
flexible, cost-effective, and simple to adapt by a 
compounding pharmacist at the clinical site. Many 
commercially available medications are not 
manufactured in suitable dosage forms for these special 
populations, e.g., liquid formulations for children and 
those who may be unable to swallow 
tablets.Additionally, when drug shortages occur or for 
the treatment of rare diseases, compounded products 
have a place in practice. Examples of altered drug 
products include topical ointments, eye drops, solid or 
liquid oral dosage forms, and intravenous infusions. 
Compounding also has a place in veterinary practice, 
where medicines may be altered to suit  drug 
absorption, metabolism, and swallowing abilities of 
different species.The use of small-scale compounded 
medications carries certain risks, as they are not 
assessed for product quality, stability, or efficacy. The 
importance of a collaborative, team-based approach to 
patient care and safety has been well established within 
the health field.The requirement for alternative 
medications and dosage forms may be determined by 
the patient‘s general practitioner who prescribes the 
medication or other allied health professionals:  a 
speech pathologist who identifies a swallowing 
difficulty, a physiotherapist applying ultrasound, which 
may interfere with transdermal drug delivery, or an 
occupational therapist identifying that a patient is 
unable to physically manipulate their current 
medication or its packaging. This highlights the 
importance for other members of the health care teams 
to have knowledge and understanding of compounded 
medications. Among elderly patients, the incidence of 
dysphagia is reportedly as high as 7%–13%, making 
utilization of available oral dosage formulations 
unfeasible or unsafe. Similarly, Canadian hospital 
pharmacists often encounter patients with oral, neck, or 
gastric cancer, which may make commercial solid 
dosage formulations impossible to use. Based on 
pharmacists‘ perspective, using more extemporaneous 
prepared products could also make sense economically. 
‗The significant therapeutic improvement and some 
cost savings may be gained‘ by the rational use of 
extemporaneously prepared medicines. Pharmacists 
that did not provide compounding service cited by the 
main reason as not receiving prescriptions that required 
compounding (63.6% of non-compounder 
pharmacists). In about 33% of the compounded 
products, they indicated patient-specific reasons. In 
about 10% this reason concerned a strictly defined 
pharmaceutical care issues. Some researchers 
conclusively said that 73.2% pharmacists reported their 
goal in providing full pharmaceutical care to their 
patients was the most important motivator. The main 
reasons for the decision to provide compounding 
service were want to provide full pharmaceutical care 
to patients (73.8% of compounder pharmacist) and 
responding to requests by prescribers. Most community 
pharmacists (nearly 70%) accepted compounding as a 
component of pharmaceutical care. In most of the 
studies, major reasons stated by physicians for 
prescribing extemporaneous products were that they 
worked well for certain conditions and that the product 
was not available commercially [1-7]. 
 
Evaluation of the Need 
 Soluble or dispersible tablets may be a useful and 
convenient alternative to the preparation of liquid 
extemporaneous products. Some tablets can be 
dispersed or crushed and information on this  
aspect can be obtained from the Medicines 
Information Section within the healthcare setting. 
In this case, the dose should be prepared and 
administered immediately. In general, compressed 
tablets or tablets which are scored or just film 
coated can be crushed whereas modified release 
tablets cannot.
 If a particular medicine is not available as a liquid 
formulation, another medicine from the same 
therapeutic classification may well be used,  such 
as the use of a less potent steroid rather than 
diluting a potent one.
 Using a suitable preparation intended for a 
different route of administration, for example, 
using an injectable solution orally.
 Use of a ‗specials‘ preparation manufactured in 
licensed premises (Specials are medicines made in 
larger volumes by a licensed manufacturer) [7].
Considerations before compounding 
 Commercially availability of drug in dosage 
form, strength, and packaging
 Ingredients, intended use, dosage, and method 
of administration concern
 Education, skill   and expertise to drug 
compounding
 Proper equipment, supplies, chemicals and the 
guidelines delineated in us pharmacopeia
 An alternative by which the patient will 
receive a benefit
 Safety of the compounded product
 Patient necessary storage facility, if required,
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 Necessary calculations to prepare the product
 Necessary documentation to complete 
preparation
 Literature reference that might provide 
information on use, preparation, stability, 
administration
 Expected duration of therapy
 Some basic quality control to check the 
product prior to dispensing (e.g., capsule 
weight variation, pH, visual observations)
 Ingredient identity, quality, and purity
 Corrective methods
 Physico-chemical incompatibilities [5,6]
 
Economic Considerations: The most significant factor 
which limits prescribing of compounded  medicines 
was that patients did not want products due to these 
products were not covered by the national insurance. 
Furthermore, for doctors not prescribing  these 
products, the major barrier to prescribing was their lack 
of knowledge of the products. Most responding doctors 
do not prescribe medications that require compounding 
because they lack trust in the quality of the 
compounded formulations. However, most of the 
doctors expressed a desire to learn more as shown in 
having access to information about the usefulness of 
extemporaneous products.There are at least two 
different economic considerations in making the 
decision to compound prescriptions; these include (a) 
pharmacist compensation and (b) health-care costs. The 
pricing of a compounded prescription should include 
consideration for pharmacodynamic and 
pharmacotherapeutic decision making, formulation 
expertise, time, and reimbursement of materials. 
Compounding prescriptions can be attractive 
professionally and financially. Compounding 
prescriptions can be a way of lowering the cost of drug 
therapy. In some cases, it is less expensive for the 
pharmacist to prepare a specific prescription for the 
patient, which may mean the difference between the 
patient actually obtaining the drug or doing without it. 
If compounding a prescription results in a patient being 
able to afford the drug therapy, it must be considered. 
An interesting example involves the drug 4- 
aminopyridine. Although physicians had been 
prescribing unapproved versions of the drug for up to 
20 years, it was not until the drug was studied 
systematically that rare seizures were discovered as a 
potential side effect. In this case, the medical 
profession pushed for an approved version to be 
marketed, rationalizing that if a seizure occurred in the 
context of a patient taking an FDA-approved 
alternative[4-10]. 
 
Compounding Factors 
 
Stability: One key factor in compounding prescriptions 
is stability. The more common types of stability of 
which compounding pharmacists should be aware 
include chemical, physical, and microbiological. 
Whereas commercially manufactured products are 
required to possess an expiration date, compounded 
products are assigned a beyond-use date. There are 
numerous sources of information that can be used for 
determining an appropriate beyond-use date, such as 
chemical companies, manufacturers literature, 
laboratory data, journals, and published books on the 
subject. Generally, most pharmacists prepare or 
dispense small quantities of compounded products; 
recommend storage at room, cool, or  cold 
temperatures; and use a conservative beyond-use date. 
For nonaqueous liquids and solid formulations (for 
which the manufactured drug product is the source of 
active ingredient)— The beyond-use date is not later 
than 25% of the time remaining until the product‘s 
expiration date or 6 months, whichever is earlier. A 
USP or NF substance is the source of active 
ingredient— The beyond-use date is not later than 6 
months. For water-containing formulations (prepared 
from ingredients in solid form)—The beyond-use date 
is not later than 14 days when stored at cold 
temperatures. For all other formulations—The beyond- 
use date is not later than the intended duration of 
therapy or 30 days, whichever is earlier. These beyond- 
use date limits may be exceeded when there is 
supporting valid scientific stability information that is 
directly applicable to the specific preparation (i.e., the 
same drug concentration range, pH, excipients, vehicle, 
water content). For example, active ingredients 
containing an ester functional group, such  as aspirin 
and penicillins, are susceptible to breakdown by 
hydrolysis, while those containing aldehyde or 
hydroxyl groups, such as testosterone and dopamine, 
undergo oxidative decomposition. A 10°C increase in 
temperature can result in a 2–5-fold faster rate of 
degradation. The instability of dapsone suspensions 
prepared in Oral Mix and stored at 25°C may be 
explained by a Maillard reaction between the sucrose  
in the vehicle and the amino groups of the dapsone.The 
results of this study have demonstrated the stability, for 
up to 90 days, of dapsone suspensions (2 mg/mL) 
prepared from commercial tablets in Oral Mix SF and 
stored at 5°C and 25°C or prepared in Oral Mix and 
stored at 5°C, in amber plastic bottles and amber  
plastic syringes. These suspensions should be shaken 
before use[2],[5],[6], [11], [12]. 
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Exhibit 1:Common degradation pathways of active drugs in compounded products* [2,5] 
Pathway Factors 
determining 
degradation 
rate 
Susceptible functional 
groups 
Examples 
Oxidation Concentration 
of drug, 
temperature, 
catalysts, 
solvents, light 
and excipients 
Aldehydes, alcohols, 
phenols, alkaloids, 
unsaturated alkyl chains, 
carboxylic acids 
Paracetamol, progesterone, testosterone, quinine, oils 
(unsaturated fats) such as soybean and corn oil, 
essential fats, atorvastatin, atenolol 
(O2 
dependent) 
Esters, amides, lactones, 
ethers, lactams, imines, 
acetals, anhydrates, 
sulfonamides 
Aspirin, vigabatrin, norfloxacin, omeprazole, 
simvastatin (statins), baclofen, diphenoxylate, 
methylphenidate, lignocaine, sildenafil, penicillins, 
cephalosporins, diazepam, digoxin, heparin, 
captopril, hydrocortisone 
*Drug molecules with more than one functional group can be more easily degraded. In fact, many drugs contain 
more than one functional group, being susceptible to both oxidation and hydrolysis, e.g. atenolol (contains amide 
and alcohol groups) 
 
It is essential that the active ingredient does not interact 
with any excipients originating from the dosage form 
being crushed for reformulation (e.g. tablet lubricants 
and fillers), or from additives in the new formulation 
(antioxidants, preservatives, suspending agents, 
colourants, emulsifiers). Interactions with other 
ingredients can result in physical instability of the 
product, such as precipitation of the active drug or 
phase separation (‗cracking‘) of a cream, affecting drug 
solubility, absorption and bioavailability.To minimize 
the risk of a compounded medicine degrading, short- 
term expiry dates are used (e.g. 28 days for oral and 
topical products, or 24 hours for parenteral 
formulations), unless stability studies have been 
conducted and indicate otherwise [2,5]. 
 
Potential Risks:FDA-approved drugs are made and 
tested in accordance with GMPs, which are federal 
statutes that govern the production and testing of 
pharmaceutical products. In contrast, compounded 
drugs are exempt from GMPs, and testing to assess 
product quality is inconsistent. Unlike FDA-approved 
drugs, pharmacy-compounded products are not 
clinically evaluated for safety or efficacy.The NABP 
further describes compounding as the result of a 
practitioner‘s prescription drug order based on the 
practitioner/patient/pharmacist relationship in the 
course of professional practice. In addition, 
compounded preparations do not have standard product 
labeling or prescribing information with  instructions 
for safe use. Compounding pharmacies are not required 
to report adverse events to the FDA, which is 
mandatory for manufacturers of FDA-regulated 
medications. Some pharmacies engage in activities that 
extend beyond the boundaries of traditional pharmacy 
compounding, such as large-scale production of 
compounded medications without individual patient 
prescriptions, compounding drugs that have not been 
approved for use in the US, and creating copies of 
FDA-approved drugs. Compounding drugs in the 
absence of GMPs increases the potential  for 
preparation errors. When compounding is  performed 
on a large scale, such errors may adversely affect many 
patients. Published reports of independent testing by 
the FDA, state agencies, and others consistently show 
that compounded drugs fail to meet specifications at a 
considerably higher rate than FDA-approved drugs. 
Compounded sterile preparations pose the additional 
risk of microbial contamination to patients. In the last 
11 years, three separate meningitis outbreaks have been 
traced to purportedly ‗sterile‘ steroid injections 
contaminated with fungus or bacteria, which were  
made by compounding pharmacies. US-FDA and the 
NICHD, have worked together to develop product 
labeling for pediatric patients for existing and new drug 
molecules coming to the market, if the drug has been or 
could be used in children. When compared to GMPs, 
the manufacturing standards required by FDA for 
commercial products, there are multiple recognized 
deficiencies inherent in extemporaneous formulation- 
compounding suitable for pediatric patients [11, 13]. 
Exhibit 2.Why Is Off-Label Use of Drugs in Children Still a Problem? [13] 
 Lack of specifications required for component development by compounding pharmacies. 
 No onsite testing of active ingredients and excipients for purity, potency, content and stability. 
 No onsite specifications or testing of product containers and closures. 
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Quality Control: One of the fastest growing and most 
important areas of pharmaceutical compounding is that 
of quality control. Quality must be built-in to the 
preparation from the beginning steps to evaluating the 
final preparation. The extent of quality control applied 
to a product should be proportionate with the level of 
risk the finished product could pose to the patient and 
should be judged on a case by case basis. Even where a 
given formulation has been shown to achieve suitable 
physical, chemical and microbiological stability, the 
bioavailability and palatability of the preparation may 
be unproven.Consideration should be given to the 
individual patient‘s age and condition, whether the 
product will be ingested or used topically, as well as  
the potency of, and risk posed by, the active substances 
and/or excipients. Where it is not practical to carry out 
this testing (e.g. due to the batch size, urgency, etc.), 
other suitable methods should be implemented to 
ensure that the appropriate quality is achieved, in 
accordance with the risk assessment carried out. At a 
minimum, the starting materials and finished product 
should be examined visually before supply to a 
patient.There are several quality control tests that can 
be done within the pharmacy and others can be  sent to 
a contract laboratory. The following quality control 
tests can be considered for the respective dosage forms. 
 Oral and topical liquids (solutions, suspensions, 
emulsions): Weight/volume, pH, specific gravity, 
active drug assay, globule size range, rheological 
properties/pourability, physical observation (color, 
clarity), physical stability (discoloration, foreign 
materials, gas formation, mold growth).
 Hard Gelatin Capsules: Weight-overall average 
weight, weight individual weight variation, 
dissolution of capsule shell, disintegration and/or 
dissolution of capsule contents, active-drug assay, 
physical appearance (color, uniformity, extent of
fill, locked), physical stability (discoloration, 
changes in appearance). 
 Ointments, Creams and Gels: Theoretical weight 
compared to actual weight, pH, specific gravity, 
active drug assay, physical observations (color, 
clarity, texture-surface, texture-spatula spread, 
appearance, feel) and rheological properties.
 Suppositories, Troches, Lollipops and Sticks: 
Weight, specific gravity, active drug assay, 
physical observation (color, clarity, texture of 
surface, appearance, feel), melting test, dissolution 
test, physical stability.
 Parenteral preparations: Weight/volume, 
physical observation, pH, specific gravity, 
osmolality, assay, color, clarity, particulate matter, 
sterility, pyrogenicity [5,6], [14].
 
Compounding Support: Numerous agencies, 
companies, organizations, etc., are available to assist 
pharmacists in compounding. Information, chemicals, 
supplies, and equipment are readily available. 
Chemical and supply companies have increased in size 
and number in recent years and many provide 
information on compounding, incompatibilities, and 
stability. Specialty compounding organizations have 
developed over recent years and generally provide full- 
line services and products to the compounding 
pharmacist. Many national organizations provide 
continuing professional education programs in both 
non-sterile and sterile compounding. These entities 
provide services to compounding pharmacists ranging 
from selling only compounding aids to providing only 
chemicals. Others offer additional services to include 
formulas as well as consulting  expertise by telephone 
or via the internet. This service can assist in the process 
of compounding a particular product that may be 
difficult. 
 Site-to-site variations in compounding procedures, equipment, and the degree of product 
handling/manipulation. 
 Lack of environmental control, which might lead to unintentional contamination and generation of 
degradation products due to inconsistent exposure to light, temperature and processing controls. 
 Lack of testing of finished products for purity, potency, content or stability. 
 Stability data for establishing expiry dates of compounded products are derived from published data, 
where preparation methods likely vary from local methods, or are simply default expiry periods 
defined by regional pharmacy regulations and ―best practices‖. 
 Published preparation methods provide only a portion of the information needed to  consistently 
prepare a stable potent final product. 
 Limited options available to mask bad-tasting active ingredients. 
 The dose administration technologies used such as droppers, syringes, scoops, spoons, etc., vary 
between sites and between prescription fills. 
 Weak regulatory oversight. 
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 Exhibit 3. MHRA (2007) in the context of extemporaneous preparation[14] 
 Extemporaneously prepared medicines should be formulated and prepared in compliance with current 
legal requirements and standards. 
 Preparation and quality control arrangements are to be documented and in compliance with current 
GPP requirements. 
 All products prepared should be quality suitable for their intended use 
 Products are released for patient use only by a pharmacist. 
 Documentation and records should comply recommendations in this guidance document. 
 
Training and Experience: Pharmacists involved in 
upgrading and increasing the traditional aspects of 
extemporaneous compounding need to keep current 
with all the new tools of their trade, retrieve the old 
from storage, and put in a bit of practice using their 
scientific background and their art before they will be 
comfortable in exhibiting their skills. The pharmacist 
must ensure that the staff, facilities and systems in 
place are capable on a day-to-day basis of providing an 
adequate quality service able to meet the needs of 
patients. There should be an adequate number of 
competent personnel at all times. All staff involved in 
extemporaneous preparation must receive training 
Appropriate to their role. Typically, this will: (a) 
provide them with knowledge in good extemporaneous 
preparation practice, local practices including health 
and safety, formulation, expiry periods and quality 
assurance appropriate to the level of involvement, 
assessment of risk and medication error potential, the 
pharmacy, its products and services provided (b) 
demonstrate competency in the necessary 
extemporaneous preparation skills and pharmaceutical 
calculations and dilutions. During training, staff must 
be carefully supervised and checked and trainees must 
understand the limits of their responsibilities.When 
considering providing additional services of 
compounding in an institution, pharmacists should not 
expect that this will change a great deal of their  
practice in time consumed for compounding. A written 
training program should be available and completion of 
training should be documented. This applies to all 
personnel working in the preparation area, including 
those not directly involved in preparation processes 
(e.g. cleaning staff). [14]. 
 
Equipment: The equipment needed will be determined 
by the type and extent of the services one chooses to 
provide. Many pharmacies already have clean air 
environments (e.g., laminar air flow hoods, isolation 
barrier systems) where aseptic compounding of sterile 
solutions is performed. These same units can be used to 
compound other sterile preparations such as eye drops. 
A balance, preferably electronic, is essential. Ointment 
slabs (i.e., pill tiles), along with spatulas of different 
types and materials, should be purchased. A few 
mortars and pestles (i.e., glass, ceramic, plastic) and 
some glassware should be secured. A policy for the 
segregation of specific equipment for certain product 
types, including cytotoxic drugs and external products, 
should be available; this should take into account local 
COSHH assessments. Equipment should be calibrated 
and validated to demonstrate satisfactory performance. 
Measures should be calibrated for specific volumes and 
should have levelling lines. Glassware should be 
inspected regularly, before and after each use, for chips 
and cracks, and replaced as necessary. Consideration 
should be given to the merits of other materials. 
Stainless steel of a suitable grade is a good material but 
care must be taken with some agents as it is susceptible 
to oxidation. Plastics are susceptible to surface 
scratches and stains. The accuracy of balances should 
be checked on a regular basis and records of this 
process maintained.It may not be necessary to buy a 
roomful of equipment, but one should purchase what is 
needed to start the service and should build on it as the 
service grows and expands to different arenas. Much of 
the equipment used today in compounding has 
changed. Today, electronic balances are used more 
often than torsion balances; micro-pipets are 
commonplace; and ultra-freezers are sometimes 
required in addition to standard refrigerator freezers. 
This area is constantly changing and the compounding 
pharmacist should be aware of the available technology 
to prepare accurate and effective prescriptions. 
Becoming acquainted with the local representative for  
a laboratory supply company is helpful [2], [6], [14- 
19]. 
 
Environment: A separate area for traditional 
compounding is recommended, rather than simply 
cleaning off a small area of the dispensing counter. The 
compounding pharmacist needs a clean, neat, well-lit 
and quiet working area. If aseptic compounding is 
considered, a clean air environment (e.g., laminar air 
flow hood, isolation barrier system) should be used. 
The actual facility to be used depends on the level and 
volume of compounding to be done. Extemporaneous 
compounding takes place in community and hospital 
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pharmacies. There are usually specialist compounding 
pharmacies in major towns and cities, but any 
pharmacy may undertake compounding as long as they 
have appropriate facilities according to state-based 
legislation   (e.g.   allocated clean bench, specific 
compounding equipment). There should be a dedicated 
facility/room   for extemporaneous  preparation. 
However, for pharmacies preparing small quantities of 
a limited range of products for immediate dispensing 
then a designated area or temporarily designated area is 
permissible. The area must be clearly demarcated 
during preparation.Measures must be taken to reduce 
any risk of cross- contamination. Only one product 
should be handled at a time. Premises and equipment 
should be easy to clean. Following maintenance or 
repair, thorough cleaning and, where appropriate, 
disinfection  should  take  place.  Environmental 
conditions, including   temperature, humidity and 
lighting, must be adequate to permit safe and 
comfortable preparation of medicinal products to limit 
the degradation of ingredients. Facilities should be laid 
out in a way to provide adequate space for the activities 
undertaken. Work should flow logically between 
working areas without the risk of product cross- 
contamination. Complex compounding is performed in 
a pressurized clean room using a laminar flow cabinet, 
cytotoxic drug safety cabinet or an isolator. Many 
public and private hospitals maintain large aseptic 
compounding facilities to provide individualized 
dosing or commercially unavailable formulations. 
Areas and equipment should be cleaned effectively 
with a suitable detergent before and after use. 
Equipment should be rinsed with an appropriate grade 
of water after washing (potable or sterile water for 
irrigation/injection) and then dried. Critical surfaces 
should be effectively sanitized with a suitable agent 
such as 70% alcohol before use. Sinks should be 
available for washing up of equipment, with separate 
facilities for handwashing. Sinks should be a suitable 
distance away from the preparation areas to reduce the 
risk of microbial contamination from water splashes. 
Washing and cleaning activities should not themselves 
be a source of contamination. All equipment should be 
visibly clean prior to use. Ensure that all residues of 
cleaning agent have been removed Containers and lids 
should be checked to ensure that they are clean and dry 
before use. Adequate pest control measures should be 
taken. [6], [10], [19] 
 
Formulas: Consistency of the compounded product is 
important. Formulas should be developed or obtained 
and tried to assure that each time an extemporaneous 
product is prepared, the methods used, ingredients 
added, and the order of steps is documented. This 
accomplishes three things. First, it provides the 
methodology for each person involved or requested to 
provide such service the information necessary to do so 
properly. Second, it provides consistency from batch to 
batch. Third, if the product does not turn out the way 
expected, a stepwise methodology exists for reviewing 
and determining what happened and if revisions and 
improvements are needed [6], [15]. 
 
Chemicals and Supplies: If one is going to prepare a 
topical product, a vehicle (e.g., cream, ointment, gel) 
and the active ingredients (e.g., either finely ground 
product from an available tablet or injection or 
pharmaceutical-grade chemicals) would be required. 
One needs proper dispensing containers for the 
medication. In short, a relationship with providers that 
carry chemicals and supplies is important. Pharmacists 
have been using chemicals and other materials for 
prescription compounding throughout history. In the 
past, these chemicals and materials have been obtained 
from natural products, raw materials, and household 
ingredients. Today, compounding pharmacists use 
chemicals from various reliable commercial sources, 
depending on their availability [9], [15-18]. 
 
Documentation: These give processing, packaging and 
release instructions. For products regularly prepared, 
master documents which combine the specification and 
product specific instructions should be produced and 
independently checked. Alternatively, a simple final 
product specification may be produced in addition to 
the master document. Master documents should be 
clear and detailed and should have a standardized style 
within any one pharmacy. Simple stepwise instructions 
for preparation, along with any specific notes or 
cautions (e.g. COSHH requirements) should be 
included on the master document for each product. A 
record should be kept of the key stages of processing, 
packaging and release of products to provide an audit 
trail of the quality relevant facts of the history of an 
extemporaneous product during preparation. This is 
normally achieved by completion of an individual 
worksheet, usually by photocopying the master 
document. Worksheets will vary for each pharmacy but 
should include: the name and formula of the product, 
and the source of the formula; a unique identification 
number to enable traceability; the manufacturer, batch 
numbers of each starting material (or QC reference 
number); the date of preparation etc. Labels must 
comply with all statutory and professional 
requirements, and should include the following 
information: the name of the product, and where 
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necessary the nature of the salt and any waters of 
crystallization; quantity and strength of active 
ingredients; the pharmaceutical formetc [6], [20]. 
 
Types of Compounding 
Active pharmaceutical ingredients can be incorporated 
into a wide array of products including creams, eye 
drops, nasal sprays, oral dosage forms or intravenous 
infusions. In Australia, products may be classified into 
simple or complex compounding (Table 1). Simple 
compounding can be performed by any pharmacist 
and is a core competency of pharmacy training. 
Complex compounding requires additional training 
and evidence, as described by the Pharmacy Board 
of Australia‘s guidelines on compounding.Finland, 
Italy, and Scotland prepared mainly powder, while 
Belgium, Croatia, France, and Switzerland 
prepared mainly capsules. Practice in Germany, 
Spain, and Slovenia involved preparation of a less 
well-defined combination of liquid, powders, and 
capsules. 
 
Table 1: Classification of simple versus complex compounding [5] 
Type Explanation Examples 
Simple All pharmacists have training during their 
undergraduate degree to prepare these 
products. 
Involves well-established preparations 
published in reputable literature, e.g. the 
Australian Pharmaceutical Formulary and 
Handbook, or formulae for which some data 
are available regarding quality, stability, 
safety, efficacy and rational design. 
Topical creams, ointments, lotions, gels, e.g. steroids, 
hormones, coal tar, cholestyramine. 
Oral liquids (solutions, suspensions, emulsions, 
mixtures, elixirs), tinctures, e.g. omeprazole suspension. 
Capsules, tablets, powders, e.g. ethinylestradiol 
capsules. Suppositories, pessaries, e.g. paracetamol, 
clotrimazole 
Complex Pharmacists require further postgraduate 
training in association with self-assessment 
of relevant competencies  and 
documentation of the specific competencies 
in a continuing professional development 
plan. Specialized facilities (sterile room 
with positive pressure) and equipment 
(laminar flow isolator, dry heat sterilization 
oven) are also required. 
Parenterals, e.g. morphine, clonidine. Ingredients with a 
safety     hazard,     e.g.     cytotoxics,      hormones 
Single unit micro-dose (<25 mg of drug or no more than 
25% w/v of a dosage form), e.g. naltrexone. Modified- 
release dosage forms, e.g. levothyroxine (T4), 
progesterone capsules 
Ophthalmic preparations, e.g. phenylephrine, 
tropicamide, ciprofloxacin 
 
 
Ambulatory-Care Compounding: If individuals can 
walk, they are considered mobile or ambulatory (i.e., 
they are not bedridden). Consequently, most 
pharmacists are involved in ambulatory care, and most 
ambulatory patients are outpatients. Actually, the term 
can also be applied to home-care patients and even 
institutionalized patients who are mobile. One general 
characteristic of ambulatory patients is that they are 
generally responsible for obtaining their own 
medication, storing it, preparing it (if necessary), and 
taking it. It seems almost incongruous that in health 
care today as we become more aware that patients are 
individuals, respond as individuals, and must be treated 
as individuals that some health-care providers appear to 
be grouping patients into categories. They are grouped 
in categories for treatment, for reimbursement from a 
third party, or for determining levels of care in 
managed-care organizations and using fixed-dose 
products provided by pharmaceutical manufacturers 
 
that are available because the marketing demand is 
sufficiently high to justify their manufacture and 
production. Why should the availability or the lack of 
availability of a specific economically profitable 
commercially available product dictate the therapy of a 
patient? Pharmacists have an opportunity to extend 
their activities in patient care as the emphasis continues 
to shift from inpatient care to ambulatory care. 
Ambulatory care, however, is so diverse and involves 
so many disciplines that sometimes it is difficult to 
understand it; and, it changes rapidly. Also, ambulatory 
care could generally encourage a team approach to 
health improvement, prevention, health maintenance, 
risk assessment, early detection, management, curative 
therapy, and rehabilitation. Ambulatory care offers 
various opportunities for individualizing patient care 
through pharmaceutical compounding. In fact, it is the 
area where most compounding pharmacists‘ practice. 
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Pharmacists‘ roles in ambulatory care patients can 
include, among others 
 Dispensing
 Compounding
 Counseling
 Minimizing medication errors
 Compliance enhancement
 Therapeutic drug monitoring
 Minimizing expenditures
Most reimbursement for ambulatory patients comes 
from the dispensing or the compounding process. Little 
financial consideration is given to counseling, 
minimizing medication errors, compliance 
enhancement and therapeutic monitoring. However, 
these activities are important and should be performed. 
Because of the unique nature of compounded 
medications, counseling is an absolute must for these 
patients. From the above discussion of the activities of 
ambulatory care pharmacists, it should be evident that 
extemporaneous compounding can be vitally important 
in ambulatory patient care [6], [18-21] 
 
Hospital Pharmacy Compounding: The ever-present 
responsibility of the health-care industry is to provide 
the best available care for the patient, using the best 
means to do so, and providing that care in a conducive 
environment. This must be sufficiently economical to 
not put the institution in jeopardy of being unable to 
continue to provide the services to the community they 
serve. This requires cooperation on the part of the 
hospital administration, the medical staff, and the 
employees (nurses and pharmacists in particular as 
regards to medication usage) and must involve the 
patient. One of the effective means by which hospitals, 
and therefore hospital pharmacies, can meet these 
challenges is to consider expanding extemporaneous 
compounding services within the hospital pharmacy. 
Pharmaceutical care and pharmaceutical compounding 
can provide cost savings to the hospital  while 
providing needed options to the physician through 
problem-solving approaches and stimulating the 
hospital pharmacist through new challenges that allow 
the expression of both their skills and their art [15], 
[22,23] 
Veterinary Compounding: The first symposium on 
veterinary compounding was a significant forum for 
discussion by experts and was a pivotal point in the 
history of veterinary compounding, occurring in 
September 1993. the meeting was important because it 
assembled an impressive group of experts on veterinary 
compounding, who then set about explaining and 
defining the roles of the veterinarian and the  
pharmacist [24]. 
 
Nuclear Pharmacy Compounding:Nuclear pharmacy 
is a specialty practice of pharmacy that has been 
defined as a patient-oriented service that embodies the 
scientific knowledge and professional judgment 
required for improving and promoting health through 
assurance of the safe and efficacious use of radioactive 
drugs for diagnosis and therapy. Radioactive drugs, 
commonly referred to as radiopharmaceuticals, are a 
special class of drugs that are regulated by the FDA. 
They are unique in that they contain an unstable 
nuclide (radioactive nuclide) as a part of the compound 
designed to localize in an organ or tissue. Since 
radiopharmaceuticals are radioactive, the Nuclear 
Regulatory Commission or a similar state agency is 
involved in regulatory matters relevant to 
radiopharmaceuticals [25-27]. 
 
Risk Management 
Legal Background: Pharmacists must comply with all 
legislation relevant to the practice of pharmacy in the 
jurisdiction where the practice occurs. Failure to 
practice in accordance with these requirements may 
give rise to action by one or more responsible 
authorities. These matters may then be referred to the 
Board for appropriate action under the National Law or 
law of a co-regulatory jurisdiction. Non-compliance 
with these guidelines and the practice standards and 
guidelines relevant to compounding may also be 
notified directly to the Board for appropriate action 
under the National Law or law of a co-regulatory 
jurisdiction. Non-compliance may be reported by an 
individual lodging a notification form, or through other 
means such as notification of outcomes of audits 
carried out by a state/territory pharmacy premises 
regulatory authority or responsible body [5]. 
 
Exhibit 4.Examples of Pre-1938 Drugs That Remained on the Market as Unapproved Drugs [15] 
Acetaminophen, codeine phosphate, and caffeine 
capsules and tablets 
Morphine sulfate oral solution and tablets 
Nitroglycerin sublingual tablets 
Amobarbital sodium capsules Opium tincture 
Amyl nitrate inhalant Oxycodone tablets 
Chloral hydrate capsules, syrup, and suppositories Oxycodone hydrochloride oral solution 
 Paregoric 
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Codeine phosphate injection, oral solution, and 
tablets 
Codeine sulfate tablets 
Colchicine injection and tablets 
Digitoxin tablets 
Digoxin elixir and tablets 
Ephedrine sulfate capsules and injection 
Ergonovine maleate injection and tablets 
Ergotamine tartrate tablets 
Hydrocodone bitartrate tablets 
Hydrocodone bitartrate, aspirin, and caffeine tablets 
Hydromorphone hydrochloride suppositories 
Levothyroxine sodium for injection 
Phenazopyridine hydrochloride tablets 
Phenobarbital capsules, elixir, and tablets 
Phenobarbital sodium injection 
Pilocarpine hydrochloride ophthalmic solution 
Potassium bicarbonate effervescent tablets for oral 
solution 
Potassium chloride oral solution 
Potassium gluconate elixir and tablets 
Potassium iodide oral solution 
Salsalate capsules 
Sodium fluoride oral solution and tablets 
Thyroid tablets 
 
Alternatives to extemporaneous preparation 
 Therapeutic substitution: The use of a licensed 
medicine from the same therapeutic classification 
should be considered and may provide a better 
clinical option than the use of an 
extemporaneously prepared medicine which has 
limited data to support its formulation and 
stability. The use of a less potent steroid rather 
than diluting a potent agent is an  example where 
a therapeutic alternative may eliminate the need 
for an extemporaneous preparation.There are 
great opportunities for oncology pharmacists, as 
well as community pharmacists, as a resource for 
educating and monitoring patients receiving oral 
chemotherapy to ensure dosing accuracy, safe 
administration, and proper disposal of hazardous 
drugs.Oncology pharmacists face a constant 
challenge with patients who cannot swallow oral 
anticancer drugs, making extemporaneous oral 
liquid preparation a requirement. Improper 
extemporaneous preparation of these agents, 
especially with the traditional chemotherapy with 
a narrow therapeutic index, may increase the risk 
of over- or under-dosing [28].
 Use of an imported product: The preparation 
selected should be licensed for use in a country 
with equivalent or similar licensing arrangements 
and regulatory standards to the UK (e.g. EU, 
Canada, Australia). This will provide the 
requesting pharmacist with assurance that the 
quality, safety and efficacy of the medicine have 
been reviewed by a competent regulatory 
authority.Although clinicians do not doubt the 
efficacy and utility of captopril in managing 
children with heart failure, concerns exist about 
optimal dosing schedules and toxicity.This 
formulation is licensed in the Bristol–Myers
Squibb, Australia, but was not available in the 
UK [29]. 
 Use of a `Special' manufactured in a MHRA 
licensed unit: The benefit of purchasing a 
‗Special‘ is that the product should be made to a 
validated formula with supporting stability data in 
accordance with the principles of GMP. Licensed 
‗Specials‘ units are regularly inspected by the 
MHRA to ensure these principles are upheld. 
However, the purchasing pharmacist will still 
need to review the supporting documentation 
(e.g. specification, Certificate of 
Analysis/Conformity, BSE/TSE statement) to 
assess whether the product is of appropriate 
quality. Information on Specials manufacturers is 
available in the BNF.Specials may be used to 
meet a variety of patient needs, for example, for 
babies, children and older people, and in specific 
areas such as dermatology and palliative care 
[30].
 Use of soluble or dispersible tablets: This 
practice presents fewer health and safety risks 
than crushing tablets, which can expose the carer 
to potentially harmful dusts via inhalation. When 
dispersing tablets, the dose should be prepared 
and administered immediately, as stability cannot 
be guaranteed. It should be noted that slow or 
modified release preparations should not be used 
in this manner.If the active is not soluble, it can 
lead to inaccuracy of dosing through a lack of 
dose uniformity and reproducibility. This is a 
major consideration when no suspending agents 
are used, especially when the person 
administering the dose is inexperienced and the 
dose is small [31]. Milk has been explored as a 
vehicle in liquid formulations showing potential 
for solubilizing drugs while maintaining the 
stability of the emulsified vehicle [32].
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 Cutting tablets: Tablets cannot be cut with great 
accuracy of dose and research suggests that the 
variability may range from 50% to 150% of the 
desired dose even when using commercially 
available tablet cutters.
 Use of a preparation intended for a different 
route: The use of a suitable preparation intended 
for a different route of administration can 
sometimes be a practical alternative; for example, 
the use of an injection solution orally, or an oral 
solution rectally. However, this practice has its 
own inherent risks and the pharmacist should 
ensure that the presentation used will be absorbed 
by this route and that it will be tolerated by the 
patient. When using an injection by the oral route, 
consideration should be given to the possibility of 
rapid absorption and elevated peak levels, the 
potential for rapid drug degradation due to 
exposure to gastric acid and problems with first- 
pass metabolism. The pH of an injection should 
also be considered, as extremes of pH can 
adversely affect the gastric mucosa [20].
 
Risks associated with extemporaneouspreparation 
 Formulation failure: An insoluble drug 
suspended in a suitable vehicle may be less 
susceptible to drug degradation, but may settle 
out of the suspension over time, leading to 
sedimentation and caking. In this state, there will 
be a higher concentration of drug at the bottom of 
the bottle than at the top.In 2006, the FDA 
conducted a limited survey of compounded drugs. 
Of 36 samples tested by the FDA, 12 failed at 
least one quality test, for a failure rate of 33%. 
Further, oral hormone dosage forms containing 
multiple active ingredients showed poor content 
uniformity, with random variation in all three 
active ingredients from capsule to capsule [8], 
[20].
 Microbial contamination: The choice of 
preservative for a formulation needs to take into 
account a number of factors including pH, 
physical compatibility and the intended patient 
group. Unpreserved preparations should be stored 
in a refrigerator and assigned a short shelf-life to 
limit microbial growth.Amaximumshelf-life of 7 
days at 2–80C should be assigned to unpreserved 
oral liquid preparations unless sufficient 
validation work has been carried out to support an 
extended shelf-life.Essential macronutrients and 
micronutrients infused via PN solutions are an 
essential part of the care of infants and children 
who cannot or should not be fed enterally. Infants
and children require a greater amount of fat in 
their diet than do adults to support growth and 
development. The use of IVFE provides a 
concentrated source of calories and prevents the 
development of essential fatty acid deficiency in 
neonates fed exclusively via the parenteral route. 
The AAP recommends IVFE doses of up to 3 
g/kg/day (approximately 30 kcal/kg/day) for use 
in infants. A variety of microorganisms have been 
found in residual IVFE after completion of the 
infusion [33].Microorganisms could potentially 
be introduced during reformulation of non-sterile 
products. For example, if Candida albicans is 
inadvertently introduced into freshly prepared 
multi-dose citric acid solutions that are to be used 
orally for cough reflex testing, 
immunocompromised individuals could become 
infected.Regular monitoring of the environment, 
equipment and procedures is essential to ensure 
quality and sterility is maintained. The 
consequences of failure can be catastrophic, for 
example methylprednisolone injections from a 
single compounding pharmacy in the USA 
resulted in 137 cases of Aspergillus fumigatus 
meningitis and 12 deaths [2]. 
 Calculation errors: Common calculation errors 
associated with extemporaneous preparation 
include errors when converting units from one to 
another (e.g. milligrams to micrograms, 
conversions from weight in volume to 
millimoles). Dangers of potent ingredients and 
calculation errors, particularly where the strength 
of one or more ingredient is stated in a historical 
or non-standard fashion. Similar reports have 
originated from the US, with the death of a child 
from a super-potent imipramine liquid, and a five-
year-old child who received a 1,000-fold 
overdose of clonidine.Problems can also arise 
when doses can be prescribed as free base or salt, 
leading to potential calculation errors when 
making and administering preparations (e.g. two- 
fold errors if caffeine citrate is confused with 
caffeine base).Some of these errors have been 
attributed to inconsistent labelling approaches, for 
example, strengths expressed per millilitre or per 
5ml spoonful.Clinical pharmacists in pediatrics 
and neonatology help in dose calculation and 
dosage form modification. The increased need for 
calculations and dilutions of pediatric medicines, 
and a requirement to adjust dose of an individual 
patient based on age, gestational age, weight and 
surface area, provide a greater opportunity for a 
clinical pharmacist in medication management
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process. They can help to prepare 
pediatric/neonatal formulary [34], [41]. 
 Starting materials: Care should also be taken 
with the use of cariogenic sugars (e.g. sucrose) in 
pediatric formulations as it has been associated 
with dental cavities. It is therefore important to 
list all such excipients on the product label so that 
end-users are made aware of their presence in the 
formulation. In a 2004 published analysis 
sponsored by STD Pharmaceuticals, all samples 
purchased from three compounding pharmacies 
failed content testing for a 3% sodium tetradecyl 
sulfate solution for injection (range 2.59–3.39). 
Significant concentrations of the contaminant 
carbitol were found to be present in samples from 
all three sources (0.33–4.18), suggesting possible 
use of a non-pharmaceutical grade chemical [35].
 Patient acceptability issues: Consideration 
should be given to the palatability and 
presentation of oral liquid medicines as there is a 
good argument that taste is crucial to achieving 
good compliance in children, especially for the 
treatment of longstanding conditions such as in 
cardiology.Extemporaneously prepared oral drug 
formulations can also be plagued by poor 
palatability characteristics which can compromise 
patient adherence. This lack of child-friendly 
formulations affects 40% of the  global 
population, subjecting pediatric patients to 
avoidable adverse drug events, reduced 
compliance with medication regimens, limited 
access to new medications, and prolonged 
treatable illnesses. The pressing need for child- 
friendly, palatable medications suitable for 
administration to both infants and young children 
has been stressed (through regulatory guidance) 
by both the European Medicines Agency and the 
US FDA. Prednisone is a bitter-tasting 
corticosteroid used for its anti-inflammatory and 
immunosuppressant effects to treat a wide variety 
of conditions in both adults and children. For 
pediatric patients, an alternative form of 
administration can be produced by crushing solid 
oral prednisone formulations in order to avoid 
swallowing difficulties and/or achieve weight- 
based dosing. This approach, however, creates 
extremely poor taste and mouth feel properties 
which are objectionable to pediatric patients. 
While these limitations can be somewhat 
mitigated by the use of proprietary oral liquid 
formulations of prednisone, such products still 
retain their profoundly bitter taste characteristics. 
It is estimated that approximately half of children
refuse to take even a liquid form of prednisone, 
with the large majority of those reporting bad 
taste as the single major reason for non- 
compliance. Efforts to mask flavors using 
sweetening agents, coatings, agglomeration, or 
microencapsulation often result in poorly- 
controlled, heterogeneous particle size 
distributions that result in a gritty or granular 
mouth feel and can provide ineffective taste 
masking, characteristics that may also 
compromise patient acceptance. The design of an 
ideal paediatric formulation needs to consider the 
following factors: (i) producing minimal impact 
on the lifestyle of the child, manifesting as the 
lowest dosage frequency and a palatable product, 
(ii) provision of individualized dosing or dose 
banding appropriate for effective therapy, (iii) 
sufficient bioavailability, (iv) non-toxic 
excipients in the formulation, (v) convenient and 
reliable administration and (vi) robust production 
process at minimal cost[20], [36-39]. 
 Health and safety risks: When handling 
hazardous products, units should be equipped 
with suitable containment devices and systems 
should be put in place to eliminate the risk of 
cross-contamination.
 Therapeutic risks and clinical consequences: 
Any inaccuracy of dosing associated with 
medicines that have a narrow therapeutic index 
can lead to significant morbidity, whether due to 
under-dosing leading to treatment failure or 
overdosing leading to toxicity. By contrast, any 
inaccuracy of dosing associated with drugs with a 
wide therapeutic index may have little or no 
impact on the therapy.
 Associated clinical risk factors: The majority of 
patients receiving extemporaneously prepared 
products, in particular oral liquid medicines, tend 
to be from vulnerable patient groups (e.g. 
neonates, children, stroke victims) who are either 
unaware of ill-effects associated with their 
treatment or who cannot communicate with their 
clinician. Coupled with this, extemporaneous 
preparations may not be routinely identified as 
high-risk therapies by pharmacists and therefore 
such treatments are not commonly given the level 
of scrutiny and close monitoring they require. 
Therefore, when embarking on the use of an 
extemporaneously prepared product, the 
pharmacist should ensure that systems are  in 
place to monitor the effectiveness of the therapy 
[20].
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Risk Management 
The European Pharmacopoeia monograph on 
Pharmaceutical Preparations specifies the necessity for 
tests to be applied to particular dosage forms, as 
described in their respective dosage form monographs, 
which are also applicable in the case of 
extemporaneously prepared products. The requirements 
on testing in the European Pharmacopeia monograph 
deal with the appearance of products, identity and 
purity tests, uniformity and reference standards. The 
extent of quality control applied to a product should be 
proportionate with the level of risk the finished product 
could pose to the patient and should be judged on a  
case by case basis. Consideration should be given  to 
the individual patient‘s age and condition, whether the 
product will be ingested or used topically, as well as  
the potency of, and risk posed by, the active substances 
and/or excipients. Where it is not practical to carry out 
this testing (e.g. due to the batch size, urgency, etc.), 
other suitable methods should be implemented to 
ensure that the appropriate quality is achieved, in 
accordance with the risk assessment carried out. At a 
minimum, the starting materials and finished product 
should be examined visually before supply to a patient 
[40,41]. 
 
Role of the Pharmacists 
Compounding preparations extemporaneously on 
lawful prescription for individual patients is within the 
pharmacist‘s purview. Pharmacists and pharmacies are 
licensed and inspected by the states; if a state 
inspection uncovers ―manufacturing under the guise of 
compounding,‖ it refers the matter to the FDA, which 
can apply cGMP expectations to the 
pharmacist/pharmacy. When a pharmacist engages in 
large-scale production of preparations without 
prescription or evidence of pending refills, trending, 
etc, the practice can be regarded as manufacturing; 
cGMP compliance will be expected, including an 
approved NDA or ANDA. Today, however, 
compounding pharmacies have begun to flourish and 
are once again becoming a vital component of 
pharmacy practice. Many health care professionals 
recognize that, for some specific patient populations, 
there is a growing need to compound certain 
medications because they are not available through 
conventional manufacturing methods. Whereas the 
services provided by compounding pharmacies give 
many patients options with regard to drug therapy, 
compounding pharmacists must be properly trained to 
specialize in this aspect of pharmacy practice and must 
have the appropriate resources and references to 
compound quality medications. Pharmacists are 
responsible for ensuring that extemporaneous 
preparations are compounded according to 
compounding guidelines and standards with respect to 
purity, quality, stability, packing, record keeping, and 
other appropriate pharmacy practices. Compounding 
pharmacists must work closely with the prescribing 
physician to ensure that patient goals are met. A 
positive therapeutic outcome for the patient is the 
fundamental goal for all health care professionals, and, 
with that goal in mind, the services provided by 
compounding pharmacies can continue to make 
pharmacists an indispensable part of the health care 
team [42,43]. 
 
Epilogue 
Pharmacy compounding provides pharmacists with a 
unique opportunity to practice their time-honored 
profession. It is becoming an even more important part 
of pharmacy practice in the future, including those 
involved in community and hospital care, nursing care, 
home care, veterinary and other specialty practices.  It 
is a practice where the clinical expertise can be merged 
with the scientific expertise of pharmacists to make a 
visible pharmaceutical care. Pharmacists are to be 
encouraged more in compounding but should be aware 
of the core of formulating a specific drug product for a 
specific patient. This is important in providing 
pharmaceutical care. 
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